- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5647
10-year publication summary
|
225
|
373
|
465
|
399
|
459
|
472
|
469
|
436
|
388
|
191
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7847 |
75 |
| Takeda Pharmaceutical Company Limited | 2718 |
57 |
| Hoffmann-La Roche Inc. | 3726 |
52 |
| H. Lundbeck A/S | 1242 |
46 |
| Janssen Pharmaceutica N.V. | 3213 |
41 |
| The Regents of the University of California | 20590 |
39 |
| Sumitomo Pharma Co., Ltd. | 550 |
36 |
| Genentech, Inc. | 4090 |
29 |
| Pfizer Inc. | 3375 |
28 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
27 |
| Taisho Pharmaceutical Co., Ltd. | 855 |
27 |
| Bristol-myers Squibb Company | 4789 |
25 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 861 |
25 |
| Novartis AG | 10338 |
24 |
| Centre National de La Recherche Scientifique | 10914 |
23 |
| Merck Sharp & Dohme LLC | 3737 |
23 |
| The Johns Hopkins University | 5844 |
22 |
| BIAL - Portela & CA, S.A. | 213 |
22 |
| Osaka University | 3289 |
21 |
| AC Immune S.A. | 270 |
20 |
| Other owners | 4985 |